Treatment with rituximab in benign and malignant hematologic disorders in children.
Giulino
Lisa B
LB
Weill Medical College of Cornell University, Department of Pediatrics, Division of Hematology/Oncology, New York, NY 10021, USA.
Bussel
James B
JB
Neufeld
Ellis J
EJ
D000293:Adolescent; D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007223:Infant; D007262:Infusions, Intravenous; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab